Prescient prepares to unveil Phase 1b cancer trial findings at world’s largest haematology conference
Clinical stage oncology company Prescient Therapeutics will showcase the results of its Phase 1b study in...
Clinical stage oncology company Prescient Therapeutics will showcase the results of its Phase 1b study in...
Australian clinical stage oncology company Prescient Therapeutics (ASX: PTX) is set to present the exciting results from...
Prescient Therapeutics (ASX: PTX) to present Phase 1b cancer trial data at prestigious haematology conference
Prescient Therapeutics (ASX:PTX) has announced that its abstract for the results of a Phase 1b...
Results of a Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) Phase 1b study in T cell lymphomas have been accepted...
Prescient Therapeutics Limited (ASX: PTX) has been witnessing significant achievements and progress towards its goal...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has reported a solid end to financial year 2023...
Prescient Therapeutics is on a mission to improve outcomes for cancer patients, and it is...
Steven Yatomi Clarke – CEO and Managing Director – Prescient Therapeutics (ASX:PTX) is a clinical-stage...
Clinical stage oncology company Prescient Therapeutics Ltd (ASX: PTX) has finished off another strong quarter...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.